HDAC4 Represses P21(WAF1/Cip1) Expression in Human Cancer Cells Through a Sp1-dependent, P53-independent Mechanism
Overview
Authors
Affiliations
Cancer cells have complex, unique characteristics that distinguish them from normal cells, such as increased growth rates and evasion of anti-proliferative signals. Global inhibition of class I and II histone deacetylases (HDACs) stops cancer cell proliferation in vitro and has proven effective against cancer in clinical trials, at least in part, through transcriptional reactivation of the p21(WAF1/Cip1)gene. The HDACs that regulate p21(WAF1/Cip1) are not fully identified. Using small interfering RNAs, we found that HDAC4 participates in the repression of p21(WAF1/Cip1) through Sp1/Sp3-, but not p53-binding sites. HDAC4 interacts with Sp1, binds and reduces histone H3 acetylation at the Sp1/Sp3 binding site-rich p21(WAF1/Cip1) proximal promoter, suggesting a key role for Sp1 in HDAC4-mediated repression of p21(WAF1/Cip1). Induction of p21(WAF1/Cip1) mediated by silencing of HDAC4 arrested cancer cell growth in vitro and inhibited tumor growth in an in vivo human glioblastoma model. Thus, HDAC4 could be a useful target for new anti-cancer therapies based on selective inhibition of specific HDACs.
PXD101 inhibits malignant progression and radioresistance of glioblastoma by upregulating GADD45A.
Hu X, Zhou P, Peng X, Ouyang Y, Li D, Wu X J Transl Med. 2024; 22(1):1047.
PMID: 39568000 PMC: 11577825. DOI: 10.1186/s12967-024-05874-5.
Hsu K, Huang Y, Chu J, Huang Y, Hu J, Lin T J Enzyme Inhib Med Chem. 2024; 39(1):2406025.
PMID: 39316378 PMC: 11423540. DOI: 10.1080/14756366.2024.2406025.
Lee M, Azizgolshani N, Zhang Z, Perreard L, Kolling F, Nguyen L Nat Commun. 2024; 15(1):3635.
PMID: 38688903 PMC: 11061294. DOI: 10.1038/s41467-024-47943-9.
A glimpse into novel acylations and their emerging role in regulating cancer metastasis.
Shi H, Cui W, Qin Y, Chen L, Yu T, Lv J Cell Mol Life Sci. 2024; 81(1):76.
PMID: 38315203 PMC: 10844364. DOI: 10.1007/s00018-023-05104-z.
Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy.
Everix L, Seane E, Ebenhan T, Goethals I, Bolcaen J Pharmaceuticals (Basel). 2023; 16(2).
PMID: 37259375 PMC: 9967489. DOI: 10.3390/ph16020227.